Journal: Oncology Letters

Article Title: Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma

doi: 10.3892/ol.2024.14776

Figure Lengend Snippet: Nrf2 is differentially distributed in different cancer stages and subtypes of DLBCL. (A) Elevated NFE2L2 (Nrf2) mRNA levels in DLBCL tissues compared with in normal tissues. (B) Increased % Nrf2-positive cancer cells in advanced stages of DLBCL. (C) Higher frequency of Nrf2-positive cancer cells in the GCB subtype of DLBCL compared with that in the ABC subtype. (D) Higher Nrf2-positive cancer cell numbers in the GCB subtype across all stages of DLBCL. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.

Article Snippet: Human DLBCL cancer cell lines, U2932 (Guangzhou Ubigene Biosciences Co., Ltd.) and HT (cat. no. 60486; Bioresource Collection and Research Center, Taiwan) were cultured in RPMI-1640 supplemented with 10% FBS (Merck KGaA), 2 mM L-glutamine (Gibco; Thermo Fisher Scientific, Inc.), 10 mM HEPES (BioConcept AG), 1 mM sodium pyruvate (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO 2 at 37°C.

Techniques: Immunohistochemistry

Journal: Oncology Letters

Article Title: Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma

doi: 10.3892/ol.2024.14776

Figure Lengend Snippet: Immunohistochemical staining of Nrf2 localization in DLBCL. (A) Active Nrf2 is distributed in both the nucleus and cytoplasm, covering the entire cell (black arrows). (B) Nrf2 localized in the cytoplasm surrounds the nucleus (red arrows indicate cytoplasmic Nrf2; nucleus stained with hematoxylin). (C) Nuclear Nrf2 is predominantly observed in the ABC subtype of DLBCL and is absent in the GCB subtype. All IHC sample images are ×40 magnification. DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell.

Article Snippet: Human DLBCL cancer cell lines, U2932 (Guangzhou Ubigene Biosciences Co., Ltd.) and HT (cat. no. 60486; Bioresource Collection and Research Center, Taiwan) were cultured in RPMI-1640 supplemented with 10% FBS (Merck KGaA), 2 mM L-glutamine (Gibco; Thermo Fisher Scientific, Inc.), 10 mM HEPES (BioConcept AG), 1 mM sodium pyruvate (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO 2 at 37°C.

Techniques: Immunohistochemical staining, Staining

Journal: Oncology Letters

Article Title: Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma

doi: 10.3892/ol.2024.14776

Figure Lengend Snippet: Keap1 expression in DLBCL, especially in the advanced staged and ABC subtype. (A) KEAP1 mRNA is significantly upregulated in DLBCL compared with that in the controls in The Cancer Genome Atlas and Genotype-Tissue Expression databases. (B) Significantly higher Keap1 expression in the advanced stages of DLBCL than in the early stages. (C) Significantly higher Keap1 expression in patients with DLBCL of the ABC subtype than the GCB subtype. (D) KEAP1 mRNA expression in DLBCL cell lines (HT and U2932). *P<0.05; **P<0.01. All IHC sample images are ×20 magnification. DLBCL, diffuse large B-cell lymphoma; Keap1, kelch-like ECH-associated protein 1; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.

Article Snippet: Human DLBCL cancer cell lines, U2932 (Guangzhou Ubigene Biosciences Co., Ltd.) and HT (cat. no. 60486; Bioresource Collection and Research Center, Taiwan) were cultured in RPMI-1640 supplemented with 10% FBS (Merck KGaA), 2 mM L-glutamine (Gibco; Thermo Fisher Scientific, Inc.), 10 mM HEPES (BioConcept AG), 1 mM sodium pyruvate (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO 2 at 37°C.

Techniques: Expressing, Immunohistochemistry

Journal: Oncology Letters

Article Title: Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma

doi: 10.3892/ol.2024.14776

Figure Lengend Snippet: Increased LC3B (encoded by MAP1LC3B) expression in DLBCL. (A) Elevated MAP1LC3B mRNA expression in DLBCL compared with controls in The Cancer Genome Atlas and Genotype-Tissue Expression databases. (B) LC3B expression across the early and advanced stages of DLBCL. (C) LC3B expression in the DLBCL GCB and ABC subtypes. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; TPM, transcripts per million; IHC, immunohistochemistry; MAP1LC3B, microtubule-associated protein 1 light chain 3β.

Article Snippet: Human DLBCL cancer cell lines, U2932 (Guangzhou Ubigene Biosciences Co., Ltd.) and HT (cat. no. 60486; Bioresource Collection and Research Center, Taiwan) were cultured in RPMI-1640 supplemented with 10% FBS (Merck KGaA), 2 mM L-glutamine (Gibco; Thermo Fisher Scientific, Inc.), 10 mM HEPES (BioConcept AG), 1 mM sodium pyruvate (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO 2 at 37°C.

Techniques: Expressing, Immunohistochemistry

Journal: Oncology Letters

Article Title: Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma

doi: 10.3892/ol.2024.14776

Figure Lengend Snippet: Nitrotyrosine expression in different DLBCL stages and subgroups. (A) Nitrotyrosine-positive cells were more prevalent in the advanced stages of DLBCL. (B) Higher frequency of nitrotyrosine-positive cells was observed in the ABC subtype of DLBCL. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; IHC, immunohistochemistry.

Article Snippet: Human DLBCL cancer cell lines, U2932 (Guangzhou Ubigene Biosciences Co., Ltd.) and HT (cat. no. 60486; Bioresource Collection and Research Center, Taiwan) were cultured in RPMI-1640 supplemented with 10% FBS (Merck KGaA), 2 mM L-glutamine (Gibco; Thermo Fisher Scientific, Inc.), 10 mM HEPES (BioConcept AG), 1 mM sodium pyruvate (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO 2 at 37°C.

Techniques: Expressing, Immunohistochemistry

Journal: Oncology Reports

Article Title: Compression force promotes glioblastoma progression through the Piezo1‑GDF15‑CTLA4 axis

doi: 10.3892/or.2024.8835

Figure Lengend Snippet: Compressive stimuli regulate the expression of CTLA4 in neuroglioma cells. (A) H4 cells were subjected to 12 h of compressive stimuli and the expression of CTLA4 was analyzed using RT-qPCR. n=6 independent experiments; **P<0.01, determined by unpaired t-test. Cells transfected with (B) siCon or siGDF15 and (C) siCon or siPiezo1 were subjected to compressive stimulation for 12 h, and expression of CTLA4 was analyzed using RT-qPCR. n=3 independent experiments for each transfection procedure; *P<0.05, **P<0.01, ****P<0.0001 determined by one-way ANOVA followed by Tukey's test. (D) A proposed mechanism that promotes glioma progression through a mechanosensor that detects mechanical pressure in the brain tumor microenvironment. As GBM grows in a limited space, pressure builds between cells and surrounding tissues. The expression of Piezo1, a mechanosensor present in the cell membrane, increases, followed by the expression of GDF15. Subsequently, the immune checkpoint protein, CTLA4, is upregulated, enhancing the poor prognosis of glioma. Con, control; GBM, glioblastoma; GDF15, growth differentiation factor 15; ns, not significant; RT-qPCR, reverse transcription-quantitative PCR; siRNA, small interfering RNA.

Article Snippet: The human neuroglioma H4 cell line was obtained from Professor Sangmyung Rhee (Chung-Ang University, Seoul, Korea), and the A172 cell line was purchased from the American Type Culture Collection (ATCC).

Techniques: Expressing, Quantitative RT-PCR, Transfection, Membrane, Control, Reverse Transcription, Real-time Polymerase Chain Reaction, Small Interfering RNA

Journal: The Journal of Molecular Diagnostics : JMD

Article Title: Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test

doi: 10.1016/j.jmoldx.2024.09.001

Figure Lengend Snippet: Linearity of the OC Test. Plasma was spiked with extracellular vesicles (EVs) isolated from the COV413A ovarian cancer cell line to cover the full range of OC Test scores.

Article Snippet: Four different replicates of the highest concentration sample in the dilution series were made by spiking in EVs that had been previously isolated from conditioned media obtained from the culture of the COV413A human epithelial serous ovarian carcinoma cell line (used under license from the European Collection of Authenticated Cell Cultures) and quantitated on the Spectrodyne nCS1 particle counter (Signal Hill, CA), as previously described.

Techniques: Isolation